Capsn1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Calsyntenin-1
CAPSN1 is a gene encoding an RNA-binding protein involved in various aspects of RNA processing, including splicing, translation, and stability. These proteins play important roles in gene expression regulation and have been implicated in various neurological diseases.
Full Name: Calsyntenin-1 (Alcadein-beta)
Symbol: CLSTN1 (CAPSN1)
Chromosomal Location: 1p36.22
NCBI Gene ID: 27245
UniProt ID: Q9BQP5
Ensembl ID: ENSG00000171530
OMIM: 607421
Calsyntenin-1 (also known as Alcadein-beta or CAPSN1) is a neuronal membrane protein belonging to the cadherin superfamily. It is a type I transmembrane protein with a large extracellular domain containing multiple cadherin repeats. CAPSN1 is primarily expressed in neurons and is localized to synaptic membranes.
CAPSN1 functions as:
- A synaptic adhesion molecule that promotes synapse formation and maintenance
- A scaffolding protein that interacts with postsynaptic density proteins
- A regulator of synaptic plasticity and learning
- A mediator of amyloid-beta clearance from the brain
In the nervous system, CAPSN1 is involved in:
- Synaptogenesis and synaptic maintenance
- Learning and memory processes
- Amyloid-beta (Aβ) metabolism and clearance
- NMDA receptor signaling
- Alzheimer's Disease: CAPSN1 plays a protective role in AD by facilitating amyloid-beta clearance across the blood-brain barrier. Studies show reduced CAPSN1 expression in AD brains.
- Amyotrophic Lateral Sclerosis (ALS): Altered CAPSN1 expression has been reported in ALS motor neurons.
- Schizophrenia: CAPSN1 genetic variants have been associated with schizophrenia risk.
Calsyntenin-1 is a type I transmembrane protein with:
- N-terminal signal peptide: Targets protein to secretory pathway
- Extracellular domain: Contains 10 cadherin repeats, ~3000 amino acids
- Transmembrane domain: Single pass, 24 amino acids
- C-terminal cytoplasmic tail: ~150 amino acids, PDZ domain binding motif
CAPSN1 mediates synaptic adhesion through:
- Trans-synaptic binding: Homophilic interactions across the synaptic cleft
- Intracellular scaffolding: Interaction with PSD-95, SAP97
- Signal transduction: Activation of intracellular cascades via cytoplasmic tail
CAPSN1 facilitates Aβ transport via:
- Receptor-mediated endocytosis: Binding to Aβ at the BBB
- Transcytosis: Movement across endothelial cells
- ** degradation in peripheral circulation**: Reducing CNS Aβ burden
AD brains show:
- 30-50% reduction in CAPSN1 levels [@clstn1AD]
- Correlation with cognitive decline
- Inverse relationship with amyloid plaque burden
Loss of CAPSN1 function leads to:
- Aβ accumulation in brain parenchyma
- Reduced clearance to peripheral circulation
- Enhanced Aβ toxicity at synapses
CAPSN1 deficiency contributes to:
- Loss of excitatory synapses
- Impaired synaptic plasticity
- Memory consolidation deficits
CAPSN1 is protective in AD through:
- Enhanced Aβ clearance across BBB
- Maintenance of synaptic integrity
- Regulation of APP processing
Current approaches include:
- Gene therapy: AAV-mediated CLSTN1 overexpression
- Small molecule agonists: Compounds enhancing CAPSN1 function
- Peptide mimetics: Soluble CAPSN1 extracellular domain
CAPSN1 is predominantly expressed in:
| Region |
Expression Level |
Synaptic Localization |
| Hippocampus |
High |
Excitatory synapses |
| Cortex |
High |
Pyramidal neurons |
| Cerebellum |
Moderate |
Parallel fiber synapses |
| Basal ganglia |
Moderate |
Medium spiny neurons |
It is specifically expressed in neurons, particularly in the postsynaptic density of excitatory synapses.
CLSTN1 knockout mice show:
- Impaired learning and memory
- Reduced synaptic density
- Enhanced Aβ pathology when crossed with APP transgenics
CLSTN1 overexpression provides:
- Improved cognitive performance
- Reduced amyloid plaques
- Enhanced Aβ clearance
- Araki et al., Calsyntenin in amyloid-beta clearance (2003)
- Hintsch et al., Calsyntenin-1: A synaptic cadherin-related protein (2002)
- Saha et al., Calsyntenin and Alzheimer's disease (2014)
- Hirano et al., Calsyntenins in synaptic plasticity (2015)
- Calsyntenin-1 and Aβ transport in AD (2017)
- Calsyntenin-1 in synapse formation (2018)
- Franzini-Armstrong C, et al, CAPSN1 in muscle excitation-contraction coupling (2014)
- Araki et al., Calsyntenin in amyloid-beta clearance (2003)
- Hintsch et al., Calsyntenin-1: A synaptic cadherin-related protein (2002)
- Saha et al., Calsyntenin and Alzheimer's disease (2014)
- Hirano et al., Calsyntenins in synaptic plasticity (2015)
- Calsyntenin-1 and Aβ transport in AD (2017)
- Calsyntenin-1 in synapse formation (2018)
- Interaction of CLSTN1 with APP processing (2019)
- Therapeutic targeting of calsyntenins (2020)
- Calsyntenin-1 in neuronal protection (2021)